Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Galena Biopharma reverse merges with Sellas Life Sciences

Executive Summary

Cancer immunotherapy firms Galena Biopharma Inc. and privately held Sellas Life Sciences Group Ltd. agreed to an all-stock reverse merger in which Sellas will merge into Galena and become a wholly owned subsidiary. The combined company--to be named Sellas Life Science Group Inc.--will be 67.5% owned by Sellas and 32.5% by Galena, and will take over Galena’s Nasdaq stock listing under the new symbol SLS.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Includes Contract
    • Intra-Biotech Deal
    • Payment Includes Stock
    • Reverse Acquisition

Related Companies